-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iptacopan Hydrochloride in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iptacopan Hydrochloride in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Iptacopan Hydrochloride in Idiopathic Thrombocytopenic Purpura...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ulevostinag in Cutaneous T-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ulevostinag in Cutaneous T-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ulevostinag in Cutaneous T-Cell Lymphoma Drug Details: Ulevostinag (MK-1454) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegcetacoplan in Glomerulonephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegcetacoplan in Glomerulonephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegcetacoplan in Glomerulonephritis Drug Details: Pegcetacoplan (Empaveli, Aspaveli) is a synthetic peptide acts...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Adenocarcinoma Of The Gastroesophageal Junction Drug...
-
Product Insights
Cajuina C3
Cajuina C3 is an Onshore Wind project located in Rio Grande do Norte, Brazil. The project is owned by AES Brasil Energia SA and is developed by JMalucelli Energia S.A; Serra Verde V Energetica SA. The project is at the permitting stage. Empower your strategies with our Cajuina C3 report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HRS-5965 in Lupus Nephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HRS-5965 in Lupus Nephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HRS-5965 in Lupus Nephritis Drug Details: HRS-5965 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HRS-5965 in IgA Nephropathy (Berger’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HRS-5965 in IgA Nephropathy (Berger's Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HRS-5965 in IgA Nephropathy (Berger's Disease) Drug Details: HRS-5965 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ruxoprubart in Glomerulonephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ruxoprubart in Glomerulonephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ruxoprubart in Glomerulonephritis Drug Details: Ruxoprubart (NM-8074) is under development for the treatment...